Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239.

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J Transl Med (2015) 0.92

AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. PLoS Pathog (2015) 0.87

Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. Clin Immunol (2014) 0.80

Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach. Mol Ther Nucleic Acids (2016) 0.76

Development of a Recombinant Yellow Fever Vector Expressing a HIV Clade C Founder Envelope gp120. J Virol Methods (2017) 0.75

Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques. PLoS Pathog (2017) 0.75

Rare Control of SIVmac239 Infection in a Vaccinated Rhesus Macaque. AIDS Res Hum Retroviruses (2017) 0.75

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20

HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98

Effector and memory CTL differentiation. Annu Rev Immunol (2007) 7.17

Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A (2006) 6.82

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature (2008) 6.17

Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol (2005) 5.76

Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol (1998) 5.31

HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol (2004) 5.18

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol (2005) 4.78

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68

Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol (2005) 4.38

Challenges in the development of an HIV-1 vaccine. Nature (2008) 4.32

The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol (2006) 4.26

T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med (2000) 4.16

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71

Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity (2006) 3.67

Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol (2003) 3.64

Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol (2007) 3.61

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med (2004) 3.52

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35

A Blueprint for HIV Vaccine Discovery. Cell Host Microbe (2012) 3.27

Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24

TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol (2010) 3.21

HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med (2012) 2.72

Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J Virol (2002) 2.50

Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol (2002) 2.44

Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol (2009) 2.38

CD4-positive T lymphocytes are required for the generation of the primary but not the secondary CD8-positive cytolytic T lymphocyte response to herpes simplex virus in C57BL/6 mice. Cell Immunol (1991) 2.36

A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther (2000) 2.34

CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing. J Virol (2001) 2.34

Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25

Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics (2007) 2.14

Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A (2005) 2.10

Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med (2010) 2.07

Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87

Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J Virol (2004) 1.79

Vaccine-induced CD8+ T cells control AIDS virus replication. Nature (2012) 1.78

Hidden memories: frontline memory T cells and early pathogen interception. J Immunol (2012) 1.73

In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One (2011) 1.71

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63

DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol (2005) 1.52

Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J Virol (2006) 1.49

Cytolytic CD4(+) T cells in viral immunity. Expert Rev Vaccines (2010) 1.47

CD8 T cell competition for dendritic cells in vivo is an early event in activation. Proc Natl Acad Sci U S A (2006) 1.46

Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines (2012) 1.44

Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev (2011) 1.44

Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J Virol (2002) 1.42

Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol (2008) 1.38

HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol (2011) 1.34

Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther (2010) 1.28

Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog (2011) 1.27

The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge. J Virol (2011) 1.26

Rapid dissemination of SIV follows multisite entry after rectal inoculation. PLoS One (2011) 1.24

Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res (1999) 1.20

Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes. Virol J (2007) 1.20

Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J Virol (2011) 1.20

Cytotoxic granule release dominates gag-specific CD4+ T-cell response in different phases of HIV infection. AIDS (2010) 1.16

T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol (2010) 1.11

The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol (2010) 1.10

IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum Vaccin Immunother (2012) 1.02

Nef-specific CD8+ T cell responses contribute to HIV-1 immune control. PLoS One (2013) 0.98

A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine (2012) 0.96

Control of simian immunodeficiency virus replication by vaccine-induced Gag- and Vif-specific CD8+ T cells. J Virol (2013) 0.87

Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope. Vaccine (2008) 0.84

Simian immunodeficiency virus-specific CD4+ T cells from successful vaccinees target the SIV Gag capsid. Immunogenetics (2010) 0.84

Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques. PLoS One (2013) 0.83

HIV fragment gag vaccine induces broader T cell response in mice. Vaccine (2011) 0.81

Immunodominance of cytotoxic T lymphocyte epitopes co-injected in vivo and modulation by interleukin-12. Eur J Immunol (1996) 0.81

DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells. Vaccine (2011) 0.80

Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines. J Immunol (2004) 0.80

B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med (2015) 2.69

International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med (2016) 1.29

Three-dimensional imaging of HIV-1 virological synapses reveals membrane architectures involved in virus transmission. J Virol (2014) 0.92

Nef Is Dispensable for Resistance of Simian Immunodeficiency Virus-Infected Macrophages to CD8+ T Cell Killing. J Virol (2015) 0.87

Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques. J Virol (2016) 0.83

Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques. PLoS One (2013) 0.83

Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8+ T-Cell Responses Focused on a Single Nef Epitope Select for Escape Variants Shortly after Infection. J Virol (2015) 0.80

Simian Immunodeficiency Virus-Producing Cells in Follicles Are Partially Suppressed by CD8+ Cells In Vivo. J Virol (2016) 0.77

Improved genetic stability of recombinant yellow fever 17D virus expressing a lentiviral Gag gene fragment. Virology (2014) 0.75

Cellular Immune Responses against Simian T-Lymphotropic Virus Type 1 Target Tax in Infected Baboons. J Virol (2016) 0.75

Potent Plasmablast-Derived Antibodies Elicited by the NIH Dengue Vaccine. J Virol (2017) 0.75

Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector Against Dengue Virus in Rhesus Monkeys. J Virol (2017) 0.75